FDA approves Jakafi® (ruxolitinib) for treatment of patients with acute GVHD
Incyte announced the FDA has approved Jakafi® (ruxolitinib) for treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. Jakafi is the first and only FDA-approved treatment for this indication. May 24, 2019